Power Of Rare Disease Patient Registries Touted By US FDA, Patients
Patients describe how they connect with each other and advance research through registries; agency says it has accepted registry data as real-world evidence of a product's benefit.
You may also be interested in...
Patent office requests comments on its proposed initiatives, with continuation patents appearing a particular target. PTO asks if filing a terminal disclaimer for patents that are a variation of each other should be an admission they are obvious.
Teva’s carve-out fight with GSK over generic Coreg will see the Solicitor General weigh in. Amgen and Juno’s patent petitions remain pending, and the high court stays a Federal Circuit decision invalidating Novartis’ Gilenya patent.
Hemp industry and private attorneys glad Birenbaum, who was the chief cannabis policy advisor to governors of New York and Rhode Island, given prominent role at FDA that could spur regulatory action.